Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

Platinum‐based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to ch...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Oncol
Asıl Yazarlar: Zhao, Xiaoliang, Kim, In‐Kyu, Kallakury, Bhaskar, Chahine, Joeffrey J., Iwama, Eiji, Pierobon, Mariaelena, Petricoin, Emanuel, McCutcheon, Justine N., Zhang, Yu‐Wen, Umemura, Shigeki, Chen, Vincent, Wang, Changli, Giaccone, Giuseppe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2021
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8024728/
https://ncbi.nlm.nih.gov/pubmed/33320980
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12882
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller